Genentech to Present Data for Three Investigational Cancer Medicines

Investigational drugs developed across specific types of lung, bladder, and skin cancers.

At this year’s European Cancer Congress (ECC), Genentech will present data from 138 abstracts from several clinical studies that are supporting ongoing regulatory discussions for three investigational medicines across specific types of lung, bladder, and skin cancer.

These discussions represent significant progress for Genentech’s pipeline in the fields of cancer immunotherapy and targeted medicines.

“With our targeted medicines, cancer immunotherapies and the combination potential in our portfolio, we are committed to setting new standards for treating people with cancer,” said Sandra Horning, MD, chief medical officer and head of Global Product Development. “At the 2015 European Cancer Congress, new data will be presented for three investigational medicines that we hope will be approved within the next year, including atezolizumab for people with PD-L1 expressing lung and bladder cancer.”

Other medications in the pipeline include alectinib and cobimetinib, which recently received approval in Switzerland where it is marketed as Cotellic.

In addition to sharing results for alectinib, atezolizumab, and cobimetinib, researchers will present results across multiple tumor types from the company’s cancer immunotherapy and targeted medicines pipeline. These include CEA-IL2v, IDO inhibitor, and vanucizumab.

The ECC is set to take place from September 25 to 29, 2015, in Vienna, Austria.